FDA issues first warning letter over AI use in drug manufacturing
Regulators found the company had relied heavily on AI systems to generate key documents, including drug specifications, procedures and production records, without sufficient human oversight.
Credit: Motorolka/Shutterstock
Regulators found the company had relied heavily on AI systems to generate key documents, including drug specifications, procedures and production records, without sufficient human oversight
Register for FREE to keep reading
Join 12,000+ scientists, engineers, and IT professionals driving innovation through informatics, HPC, and simulation with:
- Insights into HPC, AI, lab informatics & data
- Curated content for life sciences, engineering & academia
- Access to Breakthroughs: real-world computing success
- Free reports & panels, including the Lab Informatics Guide
- White Papers & software updates for smarter research
Sign up now
Already a member? Log in here
Your data is protected under our privacy policy.
